Coda Biotherapeutics picks up $19 mln Series A


South San Francisco-based Coda Biotherapeutics Inc, a developer of a chemogenetic gene therapy platform for the treatment of intractable diseases, has raised $19 million in Series A financing. MPM Capital and Versant Ventures were the lead investors.

Source: Press Release